DE69830737D1 - Transgene tiermodelle für herz-hypertrophie und deren verwendungen - Google Patents

Transgene tiermodelle für herz-hypertrophie und deren verwendungen

Info

Publication number
DE69830737D1
DE69830737D1 DE69830737T DE69830737T DE69830737D1 DE 69830737 D1 DE69830737 D1 DE 69830737D1 DE 69830737 T DE69830737 T DE 69830737T DE 69830737 T DE69830737 T DE 69830737T DE 69830737 D1 DE69830737 D1 DE 69830737D1
Authority
DE
Germany
Prior art keywords
cardiac hypertrophy
animal models
transgenic animal
activity
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69830737T
Other languages
English (en)
Other versions
DE69830737T2 (de
Inventor
R Grant
N Olson
D Molkentin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Texas
University of Texas System
University of North Texas Health Science Center
Original Assignee
University of North Texas
University of Texas System
University of North Texas Health Science Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Texas, University of Texas System, University of North Texas Health Science Center filed Critical University of North Texas
Publication of DE69830737D1 publication Critical patent/DE69830737D1/de
Application granted granted Critical
Publication of DE69830737T2 publication Critical patent/DE69830737T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69830737T 1997-10-16 1998-10-16 Transgene tiermodelle für herz-hypertrophie und deren verwendungen Expired - Fee Related DE69830737T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6286497P 1997-10-16 1997-10-16
US62864P 1997-10-16
US6517897P 1997-11-10 1997-11-10
US65178P 1997-11-10
US8185398P 1998-04-15 1998-04-15
US81853P 1998-04-15
US6141798A 1998-04-16 1998-04-16
US61417 1998-04-16
PCT/US1998/021988 WO1999019473A1 (en) 1997-10-16 1998-10-16 Transgenic animal models for cardiac hypertrophy and uses thereof

Publications (2)

Publication Number Publication Date
DE69830737D1 true DE69830737D1 (de) 2005-08-04
DE69830737T2 DE69830737T2 (de) 2006-06-01

Family

ID=27490205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830737T Expired - Fee Related DE69830737T2 (de) 1997-10-16 1998-10-16 Transgene tiermodelle für herz-hypertrophie und deren verwendungen

Country Status (9)

Country Link
US (3) US6201165B1 (de)
EP (3) EP1023441A1 (de)
JP (3) JP2001520170A (de)
AT (1) ATE298793T1 (de)
AU (2) AU748334B2 (de)
CA (2) CA2306448A1 (de)
DE (1) DE69830737T2 (de)
ES (1) ES2241173T3 (de)
WO (2) WO1999019471A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019471A1 (en) * 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
CA2352599A1 (en) * 1998-11-24 2000-06-02 Gerald R. Crabtree Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
ATE422556T1 (de) * 1999-08-20 2009-02-15 Univ Texas Hdac4- und hdac5-abhängige regulation der genexpression im herzen
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
JP2003534809A (ja) * 2000-05-30 2003-11-25 メディジェーン アクチェンゲゼルシャフト 心臓病のための新規ターゲット遺伝子
JP2002078483A (ja) * 2000-06-28 2002-03-19 Takeda Chem Ind Ltd 心筋細胞の調製法および心疾患治療薬の探索法
EP2090663A3 (de) * 2000-06-28 2009-11-11 Takeda Pharmaceutical Company Limited Verfahren zur Herstellung von Herzmuskelzellen und Verfahren zum Suchen von Abhilfen für Herzkrankheiten
US7629308B2 (en) 2000-07-07 2009-12-08 Board Of Regents, The University Of Texas System Methods relating to muscle selective calcineurin interacting protein (MCIP)
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002046419A2 (en) * 2000-11-07 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
US7327862B2 (en) * 2001-04-30 2008-02-05 Chase Medical, L.P. System and method for facilitating cardiac intervention
US7526112B2 (en) * 2001-04-30 2009-04-28 Chase Medical, L.P. System and method for facilitating cardiac intervention
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
EP1605262A1 (de) * 2001-09-27 2005-12-14 Board Of Regents The University Of Texas System Methode zur Idenfitikation von Inhibitoren der Herzhypertrophie
US20030186289A1 (en) * 2002-01-22 2003-10-02 Myogen, Inc. Model cell systems for screening of anti-hypertrophic therapeutics
US20030221207A1 (en) * 2002-02-13 2003-11-27 Pharmacia Corporation, Global Patent Department Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
EP3254673A1 (de) 2002-11-13 2017-12-13 The UAB Research Foundation Apolipoprotein e-imitierende synthetische einzeldomäne-polypeptide und anwendungsverfahren
EP1593087A4 (de) * 2003-01-30 2006-10-04 Chase Medical Lp Verfahren und system zur bildverarbeitung und konturbewertung
US20040229360A1 (en) * 2003-03-13 2004-11-18 Jeffrey Robbins Cardiac-preferred genetic alteration of transgenic rabbits
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7951532B2 (en) * 2003-11-12 2011-05-31 Children's Hospital Medical Center Method of screening a midkine modulating agent
US7333643B2 (en) * 2004-01-30 2008-02-19 Chase Medical, L.P. System and method for facilitating cardiac intervention
EP1740945B1 (de) 2004-04-07 2018-09-19 Ncardia AG Nichtinvasive, in-vitro-funktionelle gewebetestsysteme
US8318488B1 (en) 2004-05-11 2012-11-27 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
JP4682310B2 (ja) * 2004-12-28 2011-05-11 独立行政法人産業技術総合研究所 天然型ｌ−システインまたはその誘導体を用いたホタル発光基質の生合成システム及び本システムを含んだ発光基質溶液
ES2387682T3 (es) * 2005-01-10 2012-09-28 Debiopharm S.A. Utilización de un undecapéptido cíclico para la preparación de un medicamento administrable durante situaciones isquémicas miocárdicas
EP1945242A2 (de) * 2005-07-22 2008-07-23 The Regents of the University of Colorado, A Body Corporate Hemmung von extrazellulärer signalregulierter kinase 1/2 als behandlung von herzhypertrophie und herzinsuffizienz
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
JP2010514790A (ja) * 2006-12-28 2010-05-06 リメリック バイオファーマ， インコーポレイテッド 治療処置のための方法および組成物
CA2693338A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20110218253A1 (en) * 2010-01-26 2011-09-08 Lange Nicholas T Imaging-based identification of a neurological disease or a neurological disorder
EP3189069B1 (de) 2014-07-31 2024-10-23 UAB Research Foundation Apoe-mimetische peptide und erhöhte wirksamkeit für klares plasmacholesterol
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3224381B1 (de) 2014-11-25 2019-09-04 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung von personen mit einer prädisposition für eine kardiometabolische krankheit oder davon betroffenen personen
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
KR102634017B1 (ko) * 2018-10-26 2024-02-05 고려대학교 산학협력단 심비대증 동물 모델 제작용 재조합 벡터, 상기 재조합 벡터로 형질전환된 심비대증 동물 모델 및 이의 제작 방법
US20230134859A1 (en) * 2020-03-31 2023-05-04 Sky Pharma Co., Ltd. Method for screening for, method for producing, and method for designing drug active ingredients
AU2022408189A1 (en) * 2021-12-10 2024-06-20 Aavantibio, Inc. Methods and compositions for treating mybpc3 related hypertrophic cardiomyopathy with a viral vector

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
TW215434B (de) 1992-03-07 1993-11-01 Hoechst Ag
GB9206874D0 (en) 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
WO1994021634A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Substituted alicyclic-aliphatic amine-containing macrocyclic immunomodulators
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
EP0705334A1 (de) 1993-06-14 1996-04-10 Basf Aktiengesellschaft Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
WO1995032726A1 (en) 1994-06-01 1995-12-07 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
AU682703B2 (en) 1994-06-13 1997-10-16 Alza Corporation Dosage form for administering drug in liquid formulation
US5612455A (en) * 1994-07-05 1997-03-18 Tularik, Inc. Nuclear factors and binding assay
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
BR9606603A (pt) 1995-08-25 1997-09-30 Sangstat Medical Corp Formulação de ciclosporina dispersão aquosa de nanopartículas de ciclosporina kit e processo de preparação de dispersão aquosa de partículas de ciclosporina
WO1997040163A1 (en) 1996-04-19 1997-10-30 Metin Colpan Nucleic acid vaccination for parvoviral infections
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU733883B2 (en) 1997-02-04 2001-05-31 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
WO1999019471A1 (en) * 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function

Also Published As

Publication number Publication date
AU9805898A (en) 1999-05-03
WO1999019473A1 (en) 1999-04-22
AU755428B2 (en) 2002-12-12
CA2306448A1 (en) 1999-04-22
EP1025216A1 (de) 2000-08-09
EP1025216B1 (de) 2005-06-29
JP2001520010A (ja) 2001-10-30
US6201165B1 (en) 2001-03-13
JP2008253274A (ja) 2008-10-23
US6673768B1 (en) 2004-01-06
AU748334B2 (en) 2002-05-30
AU1099299A (en) 1999-05-03
EP1645634A2 (de) 2006-04-12
US6657104B1 (en) 2003-12-02
WO1999019471A1 (en) 1999-04-22
ES2241173T3 (es) 2005-10-16
JP2001520170A (ja) 2001-10-30
EP1645634A3 (de) 2009-06-17
ATE298793T1 (de) 2005-07-15
DE69830737T2 (de) 2006-06-01
EP1023441A1 (de) 2000-08-02
CA2315244A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
DE69830737D1 (de) Transgene tiermodelle für herz-hypertrophie und deren verwendungen
DE69516160D1 (de) Dihalopropenverbindungen, diese enthaltende insektizide/acarizide mittel und zwischenprodukte zur herstellung davon
DE69529276D1 (de) Gezielte gentherapie
ATE237303T1 (de) Verwendung von zusammensetzungen mit benzoylperoxyd, glycolsäure und zink zur behandlung von dermatologischen krankheiten
ATE156331T1 (de) Zusammensetzungen auf basis von fettsäuren zur bekämpfung von bestehenden pflanzeninfektionen.
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DE3686956D1 (de) Nichtantibakterielle tetracyclinzusammensetzungen mit anticollagenolytischen eigenschaften.
MA22929A1 (fr) Produit d'hygiene personnelle avec humidificateur.
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
MY110102A (en) Methods and compositions to monitor and control termites
FI905003A (fi) Glykosaminoglykan modifierat protein.
DE69310065D1 (de) Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
DE69322766D1 (de) Formulierung und verwendung von mikroorganismen zur behandlung von vieh
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ES2138940T1 (es) Quelactantes de plata del acido etilendiamintriacetico y del acido n-acil etilendiamintriacetico.
PH24687A (en) N-1h-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents
ATE155485T1 (de) Bpc-peptide, ihre herstellung und verwendung
DE69216835D1 (de) Arylamidoalkyl- und arylaminoalkyl- n-hydroxyharnstoff- und n-hydroxyameisensäureamidderivate mit lipoxygenase inhibierenden aktivität
FI961785A0 (fi) Livsmedel
ATE84716T1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelialgewebekrankheiten.
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
DE68909465D1 (de) Behandlung von pferdeviehbestand.
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
BR9811829A (pt) Processos para fumegação do solo contendo organismos deletérios controlando ao mesmo tempo a fitotoxicidade, e, para controlar organismos deletérios no solo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee